Glaukos Co. (NYSE:GKOS) Position Increased by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. boosted its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 106.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 60,592 shares of the medical instruments supplier's stock after buying an additional 31,273 shares during the period. Glaukos accounts for approximately 1.2% of EFG Asset Management North America Corp.'s holdings, making the stock its 9th biggest position. EFG Asset Management North America Corp. owned about 0.11% of Glaukos worth $9,102,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in GKOS. Pathstone Holdings LLC boosted its holdings in shares of Glaukos by 6.3% during the 3rd quarter. Pathstone Holdings LLC now owns 22,449 shares of the medical instruments supplier's stock valued at $2,925,000 after purchasing an additional 1,326 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Glaukos by 47.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock valued at $83,609,000 after buying an additional 207,338 shares during the last quarter. Algert Global LLC grew its holdings in Glaukos by 162.4% during the 3rd quarter. Algert Global LLC now owns 13,260 shares of the medical instruments supplier's stock valued at $1,728,000 after buying an additional 8,206 shares in the last quarter. Westfield Capital Management Co. LP bought a new position in shares of Glaukos in the 3rd quarter valued at about $331,000. Finally, Harvest Fund Management Co. Ltd grew its position in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 860 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Glaukos Stock Down 1.6 %

Shares of NYSE:GKOS traded down $1.66 during trading on Friday, reaching $101.97. The stock had a trading volume of 676,518 shares, compared to its average volume of 603,441. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.77 billion, a P/E ratio of -35.53 and a beta of 0.99. Glaukos Co. has a one year low of $88.16 and a one year high of $163.71. The firm's 50-day simple moving average is $130.52 and its 200 day simple moving average is $135.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. As a group, research analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GKOS shares. Mizuho upgraded Glaukos from a "neutral" rating to an "outperform" rating and lifted their target price for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. Citigroup raised shares of Glaukos from a "neutral" rating to a "buy" rating and increased their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Piper Sandler restated an "overweight" rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Morgan Stanley lowered shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective on the stock. in a research report on Monday, December 2nd. Finally, Wells Fargo & Company boosted their target price on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $163.25.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.